WO2023036003A1 - 注射用布瑞哌唑长效制剂及其制备方法 - Google Patents
注射用布瑞哌唑长效制剂及其制备方法 Download PDFInfo
- Publication number
- WO2023036003A1 WO2023036003A1 PCT/CN2022/115484 CN2022115484W WO2023036003A1 WO 2023036003 A1 WO2023036003 A1 WO 2023036003A1 CN 2022115484 W CN2022115484 W CN 2022115484W WO 2023036003 A1 WO2023036003 A1 WO 2023036003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- particle size
- water
- particles
- brepiprazole
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 202
- 238000002347 injection Methods 0.000 title claims abstract description 24
- 239000007924 injection Substances 0.000 title claims abstract description 24
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title abstract 10
- 229960001210 brexpiprazole Drugs 0.000 title abstract 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 125
- 239000002904 solvent Substances 0.000 claims abstract description 107
- 238000001556 precipitation Methods 0.000 claims abstract description 105
- 239000000243 solution Substances 0.000 claims abstract description 105
- 238000001035 drying Methods 0.000 claims abstract description 71
- 239000007787 solid Substances 0.000 claims abstract description 53
- 238000005086 pumping Methods 0.000 claims abstract description 42
- 239000003960 organic solvent Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000004806 packaging method and process Methods 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 197
- 239000000725 suspension Substances 0.000 claims description 95
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 85
- 238000003756 stirring Methods 0.000 claims description 65
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 45
- 229920000053 polysorbate 80 Polymers 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 238000009826 distribution Methods 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 238000010008 shearing Methods 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- -1 dimethylformamide Dimethylformamide-isopropanol Chemical compound 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 claims description 3
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 claims description 3
- BHIIWXJHALLFBD-UHFFFAOYSA-N oxolane;propan-2-ol Chemical compound CC(C)O.C1CCOC1 BHIIWXJHALLFBD-UHFFFAOYSA-N 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000000843 powder Substances 0.000 description 60
- 239000002270 dispersing agent Substances 0.000 description 36
- 239000012065 filter cake Substances 0.000 description 34
- 239000000706 filtrate Substances 0.000 description 32
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 17
- 235000019799 monosodium phosphate Nutrition 0.000 description 17
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 17
- 229910000831 Steel Inorganic materials 0.000 description 16
- 239000010959 steel Substances 0.000 description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
- 229930195725 Mannitol Natural products 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000000594 mannitol Substances 0.000 description 13
- 235000010355 mannitol Nutrition 0.000 description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- 238000005520 cutting process Methods 0.000 description 12
- 238000001507 sample dispersion Methods 0.000 description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 238000000498 ball milling Methods 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- BHGCNGDTJZDAEX-UHFFFAOYSA-N n,n-dimethylformamide;propan-2-ol Chemical compound CC(C)O.CN(C)C=O BHGCNGDTJZDAEX-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the invention belongs to the field of pharmaceutical preparations, and relates to a long-acting preparation of brepiprazole and a preparation method thereof. Specifically, the present invention relates to a long-acting preparation of brepiprazole for injection and a preparation method thereof.
- Bripiprazole is an iterative product of aripiprazole, which belongs to the second generation of anti-schizophrenia drugs, and has the following structural formula:
- Bripiprazole is a partial agonist of 5-HT1A receptors and dopamine D2 receptors, and an antagonist of 5-HT2A receptors. It is clinically used for the adjuvant treatment of adult schizophrenia or adult major depression. Compared with aripiprazole, brepiprazole has lower intrinsic activity of dopamine D2 receptors, higher binding capacity of 5-HT1 and 5-HT2 receptors, lower extrapyramidal adverse reactions, and fewer adverse reactions of akathisia , is the first-line drug for the treatment of schizophrenia. However, the current marketed product of breiprazole is only a tablet for oral administration once a day, and there are still many problems in clinical use.
- CN 107536802 A discloses an aqueous suspension of brepiprazole for injection, which can achieve sustained release of brepiprazole for at least one week.
- the aqueous suspension disclosed in CN 107536802 A has slow-release characteristics, its blood drug concentration measurement in rats shows that the early release of the drug is slow, and the blood drug concentration fluctuates greatly, making it difficult to maintain a smooth and effective blood drug concentration.
- the advantage is not significant.
- the preparation of the preparation needs to rely on the addition of particle binders to form secondary particles and then suspend them in an aqueous solution. In the early stage, methods such as ball milling must be used to reduce the particle size to form primary particles, and the preparation method is complicated.
- the invention provides a long-acting preparation of brepiprazole for injection with the above advantages and a preparation method thereof.
- the preparation method of the present invention is easy to operate, and the provided brepiprazole suspension for injection has the advantages of controllable particle size, good reproducibility and stability.
- the present invention provides a method for preparing a long-acting brepiprazole preparation for injection, the method comprising the following steps:
- the organic solvent is selected from the group consisting of dimethyl sulfoxide, methylene chloride, methylene chloride-methanol, dimethylformamide, dimethylformamide Dimethylformamide-isopropanol, dimethylformamide-water, tetrahydrofuran-water, tetrahydrofuran-isopropanol, ethanol and glacial acetic acid-water;
- the breiprazole is precipitated; wherein the precipitation solvent is selected from water, organic solvents and mixtures thereof and optionally includes a surfactant, and the organic solvent is selected from ethanol and dimethyl sulfoxide,
- the surfactant is selected from Tween 20, Tween 80, Span 20, Span 40, Span 60, Span 80, succinate and glyceryl monostearate;
- each step of the method of the present invention is as follows.
- Step (a) Dissolving buripiprazole in an organic solvent to form a buripiprazole solution
- the organic solvent can be selected from dimethylsulfoxide, dichloromethane, dichloromethane-methanol, dimethylformamide, dimethylformamide-isopropanol, dimethylformamide- Water, THF-water, THF-isopropanol, ethanol, and glacial acetic acid-water.
- the organic solvent is selected from dimethyl sulfoxide, dichloromethane, dichloromethane-methanol, ethanol and glacial acetic acid-water, more preferably dimethyl sulfoxide.
- step (a) the solubility of buripiprazole in the organic solvent can be increased by heating and/or stirring, thus facilitating the dissolution process.
- the dissolution is carried out with stirring at a temperature of 40-80°C, preferably 50-70°C, more preferably 60-70°C, more preferably about 60-65°C.
- the whole process of bripiprazole dissolution is filled with nitrogen protection, which can effectively prevent the formation of unknown process impurities.
- Step (b1) Pump the brepiprazole solution into the precipitation solvent which is sheared or vigorously stirred, so that the cloth Precipitation of ripiprazole; or step (b2).
- the precipitating solvent is pumped into the sheared or violently stirred bruiprazole In the solution, the brepiprazole is precipitated
- the precipitation solvent can be water, an organic solvent or a mixture thereof, preferably water or ethanol, or a volume ratio of 20:1 to 1:20, preferably 10:1 to 1:10 , more preferably 5:1 to 1:5 water-ethanol or water-dimethylsulfoxide.
- a surfactant may be further included in the precipitation solvent to aid dispersion.
- the amount of surfactant may be 0.1-3%, preferably 0.5-2%, based on the weight of bripiprazole in the resulting system after pumping is completed.
- Surfactants include, but are not limited to, polysorbate 20 (Tween 20), polysorbate 80 (Tween 80), sorbitan fatty acid esters (Span 20, 40, 60, 80), succinates, and Glyceryl Monostearate.
- the precipitation solvent contains Tween 80, and its amount is 0.1-3%, preferably 0.5-2%, of the weight of brepiprazole in the obtained system after the pumping is completed.
- Surfactants may be contained in the precipitated bripiprazole precipitate, but can be substantially removed by washing with water in subsequent steps.
- the particle size of the product can be controlled by, for example, using a peristaltic pump to control the pumping speed of the solution.
- Pumping can be performed with a single pump head. In order to speed up sample preparation, multiple pump heads can also be used to pump simultaneously.
- the pumping speed of each pump head is 70-300mL/min, preferably 70-220mL/min, preferably 100-200mL/min, such as 150mL/min.
- the volume ratio of the pumped brepiprazole solution to the precipitation solvent can be 2:1 to 1:10, preferably 2:1 to 1:5, more preferably 1:1 to 1:4, such as 1:2.
- the purpose of controlling the particle size of the product can be achieved by controlling the cooling process.
- the faster the cooling rate the smaller the particle size of the product.
- the particle size of the precipitated sample is usually controlled by controlling the temperature of the precipitated solvent.
- the solvent precipitation temperature is -20°C to 25°C. More specifically, when water is used as the precipitation solvent, its temperature is 1°C to 25°C; when an organic solvent is used as the precipitation solvent, the temperature of the precipitation solvent is -20°C to 0°C; and when the mixture of water and organic solvent When the mixture is used as the precipitation solvent, the temperature of the precipitation solvent is -10°C to 25°C.
- the temperature for separating out the solvent is from 0°C to 20°C.
- the particle size of the product can be controlled by adjusting the shear rate or the stirring rate.
- the vigorous stirring speed is usually 200-2000 rpm, preferably 500-1000 rpm, while the shear linear speed is 1.57-15.7 m/s.
- the shear line speed is 1.57-15.7m/s, preferably 1.57-4.71m/s; and in the step (b2), the shear line speed is 7.85-12.56m/s.
- linear velocity used in this article refers to the velocity of any point on an object when it makes circular motion about a fixed axis, and is generally defined as the velocity possessed by a mass point (or each point on an object) when it makes a curved motion (including circular motion). instant speed. Its direction is along the tangent direction of the motion track, so it is also called tangential velocity. It is a physical quantity describing the motion speed and direction of a particle moving in a curve.
- the particle size of the bripiprazole particles precipitated under the above-mentioned controlled conditions is controllable in the range of 3-100 ⁇ m.
- the particle size described herein refers to the particle size corresponding to 50% of the volume distribution, i.e. Dv50, which is obtained by wet measurement using a MasterSizer 3000 laser diffraction particle size analyzer (Malvern), and is preferably 5-30 ⁇ m, more preferably 7 -20 ⁇ m.
- Step (c) Filtration, and optionally washing the solid with water
- step (c) the resulting solid is isolated by filtration and optionally washed with copious amounts of water to remove small amounts of surfactant that may be present therein so that the resulting solid is free of surfactant.
- the amount of water used for washing is generally not less than 5 times, preferably 8-20 times, more preferably 10-15 times the volume of the buripiprazole solution described in step (b1) or (b2).
- the solid obtained in step (c) is free of particulate binders such as sodium chloride.
- Step (d1) Dry the solid, and pack the dried solid and the auxiliary material solution separately to obtain the obtained the long-acting brepiprazole preparation for injection; or (d2) dispersing the solid into the excipient solution to obtain the injection Long-acting brepiprazole preparation for injection
- drying can be performed by methods known in the art, including but not limited to heating drying or heating vacuum drying, and stirring can be performed during the drying process to prevent agglomeration.
- the sterile raw material obtained after drying can be subpackaged according to a predetermined dose, and the unit dose range can be 50-400 mg, and it is packaged separately with the auxiliary material solution.
- mix the excipient solution with the sterile raw material by methods such as shaking, vortexing or ultrasonic, so that the concentration of buripiprazole is 5-40wt%, preferably 5-20wt%, more preferably 7-17wt% .
- step (d2) the solid may be directly dispersed in the excipient solution after drying in the same manner as described in step (d1) or without drying.
- Dispersion can be performed by means of stirring, shearing, ultrasound or a combination thereof.
- a suspension with a concentration of briiprazole of 5-40wt%, preferably 5-20wt%, more preferably 7-17wt% is obtained, and filled into products of different specifications.
- auxiliary material solution can comprise:
- suspending agents well-known to those skilled in the art can be used, including but not limited to polyethylene glycols (such as polyethylene glycol 4000), carboxymethylcellulose or its sodium salt, polyvinylpyrrolidone (such as PVP K12, PVPK30), hypromellose, methylcellulose, poloxamers (eg, 188, 407), or polyvinyl alcohol.
- the suspending agent is carboxymethylcellulose or its sodium salt.
- the concentration of the suspending agent is preferably 0.01%-20% (w/v), more preferably 0.05%-10% (w/v), most preferably It is 0.2%-5% (w/v).
- the concentration of the suspending agent is preferably 0.01%-20% (w/v), more preferably 0.05%-10% (w/v), most preferably 0.2%-5% (w/v).
- the wetting agent As a wetting agent, common surfactants in the art can be used, including but not limited to polysorbate (Tween 20, 40, 60, 80), sorbitan fatty acid ester (Span 20, 40, 60 , 80), poloxamer, sodium dodecyl sulfate (SDS), monoglycerides, polyoxyethylene castor oil or lecithin.
- the wetting agent is a Tween such as Tween 80.
- the concentration of the suspending agent is preferably 0.01%-20% (w/v), more preferably 0.05%-10% (w/v), most preferably It is 0.2%-5% (w/v).
- the wetting agent concentration is preferably 0.01%-20% (w/v), more preferably 0.05%-10% (w/v), most preferably 0.1%-2% (w/v).
- the pH regulator sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, tromethamine, sodium carbonate, sodium acetate, sodium bicarbonate, glucose amines, arginine, triethanolamine, citric acid and/or acetic acid.
- the pH regulator is disodium hydrogen phosphate and/or sodium dihydrogen phosphate.
- the pH value of the excipient solution is 4-9, more preferably 6-8, most preferably 6.5-7.5.
- sodium chloride sodium chloride
- glucose glucose and/or mannitol
- the osmotic pressure regulator is mannitol or sodium chloride.
- an aqueous vehicle preferably water for injection, can be used.
- the present invention provides a long-acting breiprazole preparation for injection, which is a suspension, or can be prepared as a suspension by mixing the solid contained in the preparation with an excipient solution, and the suspension contains 5-40wt% breiprazole, preferably contains 5-20wt% breiprazole, more preferably contains 7-17wt% breiprazole.
- the particle size distribution of the particles in the suspension is: not less than 3% of particles ⁇ 5 ⁇ m and not less than 15% of particles >20 ⁇ m.
- the particle size distribution of the particles in the suspension is: 3-25% of particles ⁇ 5 ⁇ m, 50-75% of particles of 5-20 ⁇ m, 10-15% of particles of 20-30 ⁇ m, and the rest > 30 ⁇ m particles.
- the particle size distribution of the particles in the suspension is: not less than 5% of particles ⁇ 5 ⁇ m and not less than 15% of particles >20 ⁇ m.
- the particle size distribution of the particles in the suspension is: 15-25% for particles ⁇ 5 ⁇ m, 20-30% for 5-10 ⁇ m particles, 25-30% for 10-20 ⁇ m particles, 20-30 ⁇ m Particles were 10-15% and the remainder were particles >30 ⁇ m.
- the particle size distribution of the particles in the suspension is: 20-23% for particles ⁇ 5 ⁇ m, 23-27% for particles 5-10 ⁇ m, 27-29% for particles 10-20 ⁇ m, 20-30 ⁇ m The particles were 13-15% and the rest were >30 ⁇ m particles.
- the formulation of the second aspect of the invention is obtainable by, or is obtained by, the method of the first aspect of the invention.
- the long-acting bripiprazole preparation for injection of the present invention is prepared by solvent precipitation, and the particle size of bripiprazole can be controlled by adjusting the process parameters, wherein the bripiprazole is in the form of anhydrous substance and injected intramuscularly Afterwards, the drug can be released quickly and reach an effective therapeutic level, and continue to release slowly to maintain the blood drug concentration at an effective therapeutic level for 30 days or longer. And after research, the use of nitrogen protection in the process of dissolving brepiprazole in an organic solvent can effectively prevent the generation of a specific unknown impurity and improve the purity of the sample.
- the sustained-release effect of the long-acting breiprazole preparation for injection of the present invention can be achieved by controlling the particle size and dosage of breiprazole, independent of excipients, and does not contain polymer excipients such as polylactic acid-glycolic acid Copolymer or polylactic acid, thereby maximizing drug loading, reducing injection volume, and maximizing patient compliance issues.
- Figure 1 shows the blood drug concentration curves of the control preparation brepiprazole suspension and the brepiprazole suspensions of Example 2 and Example 15 in rats.
- Figure 2 shows the particle size distribution of drug particles in the bripiprazole suspensions of Example 2 and Example 15.
- 3A-3D show high performance liquid chromatograms of related substances in the bripiprazole powders of Example 16 and Example 17.
- Embodiment 1 Preparation of brepiprazole suspension
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Embodiment 2 Preparation of brepiprazole suspension
- Dispersant preparation Weigh 0.1g Tween 80, 0.1g disodium hydrogen phosphate, 0.06g sodium dihydrogen phosphate, 0.9g sodium chloride in a 250mL beaker, add water 99mL, and stir until completely dissolved.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Embodiment 3 Preparation of brepiprazole suspension
- Dispersant preparation Weigh 0.1g Tween 80, 0.1g disodium hydrogen phosphate, 0.06g sodium dihydrogen phosphate, 0.9g sodium chloride into a 250mL beaker, add 170mL water, and stir until completely dissolved.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Embodiment 4 Preparation of brepiprazole suspension
- Dispersion of the suspension intermediate sample add the filter cake obtained in the sample preparation step to the dispersant 1, and use a shearing machine to disperse at a linear speed of 1.57m/s to obtain the suspension intermediate Sample, detection its drug content is 133.3%.
- Embodiment 5 Preparation of brepiprazole suspension
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Embodiment 6 Preparation of brepiprazole suspension
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by manual shaking up and down for about 5 minutes to obtain a suspension.
- Embodiment 8 Preparation of brepiprazole powder
- Embodiment 9 Preparation of brepiprazole powder
- Embodiment 15 (comparative example). Ball milling method prepares brepiprazole suspension
- the ball milling conditions are: the size of the zirconium beads is 2.2 mm, the filling amount is 60%, the ball milling speed is 1500 rpm, the flow rate is 600 ml/min, and the cooling water is tap water. After the ball milling is completed, take out the liquid medicine, dilute it with water and fill it.
- brepiprazole Immediately after the complete dissolution of brepiprazole, put the shearing head into the precipitation solvent, and adjust the shearing line speed to 2.35m/s.
- the bripiprazole solution was pumped into the precipitation solvent at a speed of 100mL/min (pumping time: 1min), suction filtered and the subsequent filtrate was removed.
- the filter cake was washed with 1000 mL of pure water, and the resulting solid was transferred to a drying oven at 40° C. for drying to obtain dry powder Example 16-1.
- the shearing head was placed in the precipitation solvent, and the shearing line speed was adjusted to 2.35m/s.
- the filter cake was washed with 1000 mL of pure water, and the obtained solid was transferred to a drying oven at 40° C. for drying to obtain dry powder Example 16-2.
- HPLC method high performance liquid chromatography (HPLC method) determination.
- octadecylsilane bonded silica gel as a filler (YMC-Pack Pro C18, 4.6mm ⁇ 150mm, 3 ⁇ m or equivalent chromatographic column); use 0.02mol/L potassium dihydrogen phosphate solution (with 10% hydroxide Potassium solution to adjust the pH to 6.5) was used as mobile phase A, and acetonitrile-water (90:10) was used as mobile phase B.
- HPLC method high performance liquid chromatography (HPLC method) determination.
- octadecylsilane bonded silica gel as a filler (YMC-Pack Pro C18, 4.6mm ⁇ 150mm, 3 ⁇ m or equivalent chromatographic column); use 0.02mol/L potassium dihydrogen phosphate solution (with 10% hydroxide Potassium solution to adjust the pH to 6.5) was used as mobile phase A, and acetonitrile-water (90:10) was used as mobile phase B.
- Table 1 and Figures 3A-3D show the detection results of related substances in the four samples of Examples 16 and 17. It is found that the addition of nitrogen protection during the dissolution of bripiprazole can effectively prevent the formation of unknown impurities (RRT0.59). (RRT: relative retention time)
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Sample dispersion Weigh 5.7 g of dry powder obtained in the sample preparation step, add 44.3 g of dispersant, and mix by shaking up and down manually for about 5 minutes to obtain a suspension.
- Example 32 The plasma concentration of brepiprazole after intramuscular injection of breiprazole suspension in SD rats
- Control preparation brepiprazole suspension (2mg/mL), which is prepared by the following method: Weigh 0.4g sodium carboxymethylcellulose, add 20g water, stir and dissolve, add 0.04g breiprazole, stir until The drug is dispersed evenly.
- Group A the contrast preparation brepiprazole suspension, 10mg/Kg, orally administered by gavage;
- B group the brepiprazole suspension of embodiment 2, 30mg/Kg, intramuscular injection of outer thigh;
- Group C the bripiprazole suspension of Example 15, 30 mg/Kg, administered by intramuscular injection of the outer thigh.
- the collected whole blood was temporarily stored at room temperature, and centrifuged at 4000rpm for 10min within 1h to separate the plasma (4°C).
- the collected plasma was stored in a -80°C refrigerator until testing.
- the plasma samples after administration were measured, and the drug-time curve was fitted with the measured blood drug concentration to calculate the pharmacokinetic parameters.
- Figure 1 shows the change curve of brepiprazole concentration in rat plasma with time.
- the samples of both Example 2 and Example 15 can achieve the effect of sustained release for 30 days, but the suspension of Example 15 prepared by the ball milling method releases slowly in the early stage of the rat body, and the blood drug The concentration fluctuates greatly, and it is difficult to maintain a smooth and effective blood concentration.
- the suspension of Example 2 prepared by the solvent precipitation method has a fast onset of action and a stable release, and the blood drug concentration shows a gentle trend, which is more conducive to clinical administration.
- Example 15 the particle size distributions of the drugs in the brepiprazole suspensions of Example 2 and Example 15 are shown in Figure 2 and Table 2. It can be seen that the particle size distribution of Example 15 is very narrow, and the particle size is mainly concentrated at 5-20 ⁇ m, and compared with Example 2, there is a lack of small particle size particles and large particle size particles. This explains why Example 15 releases slowly in the early stage and fast in the later stage in vivo. At the same time, the following table also lists the particle size distribution results of Example 3, Example 6, Example 23 and Example 24.
- Example 2 21.77% 25.05% 28.7% 14.26% 10.22%
- Example 15 1.01% 33.6% 53.92% 11.46% 0.01%
- Example 3 16.18% 28.12% 38.64% 10.3% 6.76%
- Example 6 13.59% 22.34% 37.25% 13.87% 12.95%
- Example 23 13.93% 23.78% 39.05% 12.14% 11.1%
- Example 24 18.44% 23.54% 35.17% 13.68% 9.17%
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
图3A-3D显示实施例16和实施例17的布瑞哌唑粉体有关物质的高效液相色谱图。
表1和图3A-3D显示实施例16和17的四个样品有关物质检测结果,发现布瑞哌唑溶解过程中加入氮气保护后可有效防止未知杂质(RRT0.59)生成。(RRT:相对保留时间)
0-5(μm) | 5-10(μm) | 10-20(μm) | 20-30(μm) | >30(μm) | |
实施例2 | 21.77% | 25.05% | 28.7% | 14.26% | 10.22% |
实施例15 | 1.01% | 33.6% | 53.92% | 11.46% | 0.01% |
实施例3 | 16.18% | 28.12% | 38.64% | 10.3% | 6.76% |
实施例6 | 13.59% | 22.34% | 37.25% | 13.87% | 12.95% |
实施例23 | 13.93% | 23.78% | 39.05% | 12.14% | 11.1% |
实施例24 | 18.44% | 23.54% | 35.17% | 13.68% | 9.17% |
Claims (15)
- 注射用长效布瑞哌唑制剂的制备方法,所述方法包括以下步骤:(a)将布瑞哌唑溶解于有机溶剂中形成布瑞哌唑溶液,所述有机溶剂选自二甲基亚砜、二氯甲烷、二氯甲烷-甲醇、二甲基甲酰胺、二甲基甲酰胺-异丙醇、二甲基甲酰胺-水、四氢呋喃-水、四氢呋喃-异丙醇、乙醇以及冰乙酸-水,优选选自二甲基亚砜、二氯甲烷、二氯甲烷-甲醇、乙醇以及冰乙酸-水;(b1)将所述布瑞哌唑溶液泵入到剪切或剧烈搅拌的析出溶剂中,使布瑞哌唑析出;或者(b2)将析出溶剂泵入到剪切或剧烈搅拌的所述布瑞哌唑溶液中,使布瑞哌唑析出;其中所述析出溶剂选自水、有机溶剂及其混合物并且任选地包含表面活性剂,所述有机溶剂选自乙醇和二甲基亚砜,所述表面活性剂选自吐温20、吐温80、司盘20、司盘40、司盘60、司盘80、琥珀酸酯和单硬脂酸甘油酯;(c)过滤,并任选地用水洗涤所得固体,洗涤所用水的量不少于步骤(b1)或(b2)所述布瑞哌唑溶液体积的5倍,优选8-20倍,更优选10-15倍;和(d1)干燥所述固体,并将经干燥的固体与辅料溶液分别包装,得到所述注射用长效布瑞哌唑制剂;或者(d2)在经过干燥后或者不经干燥而直接将所述固体分散至辅料溶液中,得到所述注射用长效布瑞哌唑制剂。
- 如权利要求1所述的方法,其中步骤(a)在氮气保护下进行。
- 如权利要求1或2所述的方法,其中步骤(a)中的所述有机溶剂为二甲基亚砜,并且所述溶解在搅拌下于40-80℃,优选50-70℃,更优选60-70℃,更优选约60-65℃的温度下进行。
- 如权利要求1-3中任一项所述的方法,其中在步骤(b1)或(b2)中,所述析出溶剂为水或乙醇,或者为体积比为20:1至1:20,优选10:1至1:10,更优选5:1至1:5的水-乙醇或水-二甲基亚砜,并且所述析出溶剂包含吐温80,其量为所述泵入完成后所得体系中布瑞哌唑重量的0.1-3%,优选0.5-2%。
- 如权利要求1-4中任一项所述的方法,其中在步骤(b1)或(b2)中,所述泵入通过单个泵头或多个泵头进行,并且每个泵头的泵入速度为70-300mL/min,优选70-220mL/min,优选100-200mL/min,例如150mL/min,且布瑞哌唑溶液与析出溶剂的体积比为2:1至1:10,优选2:1至1:5,更优选1:1至1:4,例如1:2。
- 如权利要求1-5中任一项所述的方法,其中在步骤(b1)或(b2)中,析出溶剂的温度为-20℃至25℃,优选0℃至20℃。
- 如权利要求1-6中任一项所述的方法,其中在步骤(b1)或(b2)中,剧烈搅拌速度为200-2000rpm,优选500-1000rpm,并且剪切线速度为1.57-15.7m/s。
- 如权利要求7所述的方法,其中在步骤(b1)中,剪切线速度为1.57-15.7m/s,优选1.57-4.71m/s;而在步骤(b2)中,剪切线速度为7.85-12.56m/s。
- 如权利要求1-7中任一项所述的方法,其中步骤(c)中所得固体不含颗粒粘合剂如氯化钠。
- 注射用长效布瑞哌唑制剂,其为混悬剂,或者可以通过混合所述制剂包含的固体与辅料溶液而配制为混悬剂,所述混悬剂含有5-40wt%的布瑞哌唑,优选含有5-20wt%的布瑞哌唑,更优选含有7-17wt%的布瑞哌唑。
- 如权利要求10所述的制剂,其中所述混悬剂中颗粒的粒径分布为:<5μm的颗粒不少于3%且>20μm的颗粒不少于15%。
- 如权利要求11所述的制剂,其中所述混悬剂中颗粒的粒径分布为:<5μm的颗粒为3-25%,5-20μm的颗粒为50-75%,20-30μm的颗粒为 10-15%,且其余为>30μm的颗粒。
- 如权利要求10所述的制剂,其中所述混悬剂中颗粒的粒径分布为:<5μm的颗粒不少于5%且>20μm的颗粒不少于15%。
- 如权利要求13所述的制剂,其中所述混悬剂中颗粒的粒径分布为:<5μm的颗粒为15-25%,5-10μm的颗粒为20-30%,10-20μm的颗粒为25-30%,20-30μm的颗粒为10-15%,且其余为>30μm的颗粒。
- 如权利要求10-14中任一项所述的制剂,其可由权利要求1-9中任一项所述的方法获得,或者由权利要求1-9中任一项所述的方法获得。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3225183A CA3225183A1 (en) | 2021-09-07 | 2022-08-29 | Long-acting brexpiprazole preparation for injection and preparation method therefor |
CN202280048496.2A CN117794517A (zh) | 2021-09-07 | 2022-08-29 | 注射用布瑞哌唑长效制剂及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111043276.4 | 2021-09-07 | ||
CN202111043276 | 2021-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023036003A1 true WO2023036003A1 (zh) | 2023-03-16 |
Family
ID=85507213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/115484 WO2023036003A1 (zh) | 2021-09-07 | 2022-08-29 | 注射用布瑞哌唑长效制剂及其制备方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN117794517A (zh) |
CA (1) | CA3225183A1 (zh) |
WO (1) | WO2023036003A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030031719A1 (en) * | 2000-12-22 | 2003-02-13 | Kipp James E. | Method for preparing submicron particle suspensions |
CN104906038A (zh) * | 2015-06-24 | 2015-09-16 | 万特制药(海南)有限公司 | 一种阿立哌唑纳米晶体及其制备方法 |
CN107536802A (zh) | 2012-04-23 | 2018-01-05 | 大塚制药株式会社 | 注射剂 |
-
2022
- 2022-08-29 WO PCT/CN2022/115484 patent/WO2023036003A1/zh active Application Filing
- 2022-08-29 CA CA3225183A patent/CA3225183A1/en active Pending
- 2022-08-29 CN CN202280048496.2A patent/CN117794517A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030031719A1 (en) * | 2000-12-22 | 2003-02-13 | Kipp James E. | Method for preparing submicron particle suspensions |
CN107536802A (zh) | 2012-04-23 | 2018-01-05 | 大塚制药株式会社 | 注射剂 |
CN104906038A (zh) * | 2015-06-24 | 2015-09-16 | 万特制药(海南)有限公司 | 一种阿立哌唑纳米晶体及其制备方法 |
Non-Patent Citations (1)
Title |
---|
YUE PENGFEI, YONG WANG, JING WAN, ZHEN-FENG WU, PENG-YI HU, QIN ZHENG, YUAN HAI-LONG, MING YANG: "The research progress of preparation methods of solid nanocrystal delivery system", ACTA PHARMACEUTICA SINICA, YAOXUE XUEBAO, CN, vol. 47, no. 9, 12 September 2012 (2012-09-12), CN , pages 1120 - 1127, XP093046144, ISSN: 0513-4870, DOI: 10.16438/j.0513-4870.2012.09.001 * |
Also Published As
Publication number | Publication date |
---|---|
CN117794517A (zh) | 2024-03-29 |
CA3225183A1 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2586306C2 (ru) | Состав с микросферами для длительного непрерывного высвобождения рисперидона | |
JP6034377B2 (ja) | アリピプラゾール医薬製剤及びその調製方法 | |
JP2003504331A (ja) | フェノフィブレート含有医薬組成物およびこれを調製するための方法 | |
KR101454086B1 (ko) | 이마티닙 메실레이트의 안정화된 무정형 형태 | |
CA3022878C (en) | Improved drug formulations | |
JP6265999B2 (ja) | 光学活性のトルバプタンを含む注射用持効性製剤及びその製造方法 | |
TW201540303A (zh) | 法洛德及其衍生物的錯合物、製備製程以及藥品組合物 | |
WO2020034989A1 (zh) | 一种可注射的药物组合物及其制备方法 | |
WO2017133662A1 (zh) | 一种紫杉醇药物组合物及其药物制剂、制备方法和用途 | |
JP2016513706A (ja) | 点眼用製剤 | |
WO2023036003A1 (zh) | 注射用布瑞哌唑长效制剂及其制备方法 | |
WO2012013116A1 (zh) | 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法 | |
CN111467344B (zh) | 一种拉西地平固体分散体及其制备方法 | |
WO2020135352A1 (zh) | 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂 | |
WO2021115389A1 (zh) | 氟维司群药物组合物、其制备方法及应用 | |
WO2019007317A1 (zh) | 一种药物组合物及其制备方法 | |
CN109419771B (zh) | 十一酸睾酮缓释药物组合物、其制备方法及用途 | |
CN112656762A (zh) | 盐酸胺碘酮纳米混悬剂及其制法和应用 | |
US20190142756A1 (en) | Drug formulations | |
EP4317156A1 (en) | Injectable lurasidone suspension and preparation method therefor | |
WO2022121961A1 (zh) | 氟维司群药物组合物、其制备方法及应用 | |
WO2023174382A1 (en) | Injectable depot formulation comprising cariprazine free base particles | |
WO2021073548A1 (zh) | 一种药物组合物 | |
CN115634197A (zh) | 一种帕莫酸托特罗定注射用混悬液制剂及其制备方法 | |
WO2023150648A2 (en) | Pharmaceutical compositions, and preparation and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22866469 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280048496.2 Country of ref document: CN Ref document number: 3225183 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202490003 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022866469 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022866469 Country of ref document: EP Effective date: 20240408 |